- Agriculture
- Antibiotic/anti-viral
- Biologics
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Emergency Services
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules
- Software & Information Technology
- Stem Cells
- Vaccines
- Veterinary Medicine
Showing 5 matches for the following: Inventor: "Li, Chuan-Yuan" ×
A genomics-based method to identify candidates for cancer treatment
Unmet Need Metastatic cancer accounts for up to 90% of all cancer deaths in the United States. Treatment at advanced stages of various cancers include immune checkpoint blockade therapy, targeted tumor therapy, cytotoxic chemotherapy, and…
A genomics-based method to identify cancer patients that will benefit from immune checkpoint therapy
Unmet Need Non-small-cell lung cancer accounts for 82% of all lung cancer diagnoses. Immune checkpoint blockade treatment is an exciting new course of action among advanced stage non-small-cell lung cancer patients. However, only a minority…
Method to sensitize cancer radiotherapy and chemotherapy
Unmet Need While radiotherapy and/or chemotherapy are used for >90% of cancer patients in clinical settings, the therapeutic outcomes are far from ideal for many types of tumors due to the development of drug resistance…
Improving immune checkpoint blockade therapy by inhibiting ATM protein
Unmet Need The great enthusiasm for immune checkpoint blockade (ICB) therapy is justified by the spectacular, durable successes it has had in some previously difficult to treat cancers such as melanoma and lung cancer. However,…
Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein
Value Proposition Immune checkpoint inhibitor therapies are exciting new drugs for treatment of cancers. Despite their efficacy for certain cancers, immune checkpoint inhibitors only effective in 10-30% of cancer patients. Because of this, there is…